Century Therapeutics (IPSC) Free Cash Flow (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly Free Cash Flow of -$25.8 million for Q1 2026, up 26.36% year-over-year from -$20.5 million in Q1 2025, and down 61.92% quarter-over-quarter from -$16.0 million in Q4 2025.
Century Therapeutics (IPSC) Free Cash Flow (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Free Cash Flow for 7 consecutive years, with -$25.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 26.36% year-over-year to -$25.8 million; the TTM figure through Mar 2026 stood at -$95.5 million (up 17.14% YoY), while the FY2025 annual figure was -$104.7 million, up 5.02% from the prior year.
- Free Cash Flow fell to -$25.8 million in Q1 2026 per IPSC's latest filing, from -$16.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $82.7 million in Q1 2022 and bottomed at -$36.0 million in Q2 2022.
- Historically, Free Cash Flow has averaged -$19.5 million across 5 years, with a median of -$27.2 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 443.62% — and 2023, when it plunged 2121.22%.
- Century Therapeutics' Free Cash Flow stood at -$1.2 million in 2022, then slumped by 2121.22% to -$27.2 million in 2023, then advanced by 10.98% to -$24.2 million in 2024, then soared by 34.1% to -$16.0 million in 2025, then plunged by 61.92% to -$25.8 million in 2026.
- Business Quant data shows IPSC's Free Cash Flow at -$25.8 million in Q1 2026, -$16.0 million in Q4 2025, and -$25.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | -20.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.53 Mn |
| Jun 30, 2026 | -20.53 Mn |
| Mar 31, 2026 | -25.85 Mn |
| Mar 31, 2026 | -25.85 Mn |
| Dec 31, 2025 | -15.96 Mn |
| Dec 31, 2025 | -15.96 Mn |
| Sep 30, 2025 | -25.78 Mn |
| Sep 30, 2025 | -25.78 Mn |
| Jun 30, 2025 | -27.91 Mn |
| Jun 30, 2025 | -27.91 Mn |
| Mar 31, 2025 | -35.10 Mn |
| Mar 31, 2025 | -35.10 Mn |
| Dec 31, 2024 | -24.22 Mn |
| Dec 31, 2024 | -24.22 Mn |
| Sep 30, 2024 | -28.33 Mn |
| Sep 30, 2024 | -28.33 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Jun 30, 2024 | -27.60 Mn |
| Mar 31, 2024 | -30.79 Mn |
| Mar 31, 2024 | -30.79 Mn |